Abstract
To provide clinicians evidence-based strategies to diagnose and treat psoriatic arthritis (PsA) patients based on involvement of the key domains peripheral arthritis, psoriasis and nails, axial involvement, dactylitis, and enthesitis, with the goal of improving outcomes for PsA patients by lessening joint pain and swelling and the degree of inflammation in the other key domains. It is also imperative to limit or eliminate progressive X-ray damage. Evidence from phase III randomized trials demonstrate that agents that inhibit tumor necrosis factor (TNF), interleukin (IL)-17, and IL12/23 relieve joint inflammation and decrease or completely inhibit radiographic progression. Agents that block TNF and IL-17 are also effective for axial disease. Additional agents effective for psoriatic arthritis but without documentation of effect on progressive damage include apremilast, abatacept, and tofacitinib. Most agents have demonstrated efficacy for treatment of enthesitis and dactylitis. A number of therapies that effectively treat the key domains of psoriatic arthritis are now available. Comprehensive assessment of patients to determine the extent and degree of domain involvement is essential to properly individualize treatment, improve outcomes, and limit progressive joint damage.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
